The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation
Our results suggest that targeting polyamine metabolism with SAM486A enhances the efficacy of KRAS<sup>G12C</sup> inhibitors and may mitigate resistance. This combination represents a promising therapeutic approach for KRAS<sup>G12C</sup>-mutant NSCLC and warrants further clinical investigation.
Authors
- Trista K. Hinz
- Carina Chipón
- Neudo Buelvas
- Antonia Martin-Martín
- Claudio Henríquez
- Lynn E. Heasley (ORCID: https://orcid.org/0000-0001-8056-0208)
- Lopez-muñoz Rodrigo
- Sergio Guzmán-Kunstmann
- Constanza Guzman-Kunstmann
- Francisca Vidal
- Franz Villarroel-Espindola
Institutions
- Austral University of Chile (CL)
- Fundación Arturo López Pérez (CL)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Biological Research
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1186/s40659-026-00679-w
- Primary Topic
- Polyamine Metabolism and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00